Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

NCT03099499 | Terminated Phase 2 DMC FDA Drug

• 1 other identifier: GYN-106
• Study Type: interventional
• Target: 19
• Locations: 1 country
• Sites: 1

Brief Summary

ONC201 is a small molecule which selectively targets the G protein-coupled receptor DRD2. Downstream of target engagement, ONC201 activates the integrated stress response (ISR) in tumor cell leading to inactivation of Akt and extracellular signal-regulated kinase (ERK) signaling as well as induction of the TRAIL pathway. ONC201 also inhibits dopamine receptor 2 (DRD2), resulting in anti-tumor responses in preclinical models. Single agent ONC201 has been examined in open-label Phase I studies in patients with advanced, treatment refractory solid malignancies. Due to its differential anti-proliferative and pro-apoptotic response in tumor cells, treatment was overall well tolerated, and the recommended phase II dose of ONC201 was set at 625mg every three weeks. An additional dose-escalation phase I study (NCT02609230) is further evaluating weekly versus three week dosing in patients with advanced solid tumors and multiple myeloma. Preliminary data from these phase I studies suggests a possible clinical benefit in patients with advanced, chemo-refractory endometrial cancers, with at least one mixed response noted in a patient with clear cell histology. Hypothesis: Single agent ONC201 will demonstrate clinical benefit in women with recurrent or metastatic endometrial cancers, especially in those women with alterations in the Phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of Rapamycin (mTOR) pathway.

Conditions

Endometrial Cancer

Outcome Measures

Primary Outcomes (2)

• Progression free survival (PFS) rate at 12 weeks

  PFS will be calculated from the day of starting the treatment until 12 weeks

  12 weeks

• Objective Response rate (ORR) as determined by Response Criteria In Solid Tumors (RECIST)1.1 criteria

  ORR will be calculated from the day of starting the treatment until disease progression

  1-2 years

Secondary Outcomes (4)

• Safety profile of ONC201 will be determined by adverse events according to Common terminology criteria for Adverse Events (CTCAE) 4.03

  1-2 years

• Duration of response

  1-2 years

• Duration of stable disease

  1-2 years

• Median progression free survival

  1-2 years

Study Arms (1)

ONC201 treatment Arm

EXPERIMENTAL

Drug: ONC201

Interventions

ONC201 DRUG

ONC201 will be administered at a dose of 625 mg by mouth weekly until disease progression, unacceptable toxicity, or if the patient discontinues for any other reason. Radiologic tumor assessment would be performed at baseline, Cycle 3 Day 1, Cycle 5 Day 1, and at the end of every 3 cycles beyond cycle 5. All patients including those removed from the study due to unacceptable toxicity, will undergo radiologic tumor assessment at the time of discontinuation (End of treatment).

ONC201 treatment Arm

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: Endometrial cancer happens only in females
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have histologically confirmed metastatic or recurrent endometrial cancer. Eligible histologies include but are not limited to endometrioid, serous, clear cell, carcinosarcoma, adenosquamous, and mixed histologies.
• Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v. 1.1
• Must have radiographic disease progression after 1 line of systemic cytotoxic therapy for metastatic disease or with progression within 12 months of completing adjuvant chemotherapy
• Available archived tissue biopsies will be provided for correlative studies
• Age \> 18 years.
• Eastern Cooperative Oncology group (ECOG) performance status of 0, 1, or 2
• Patients must have adequate bone marrow, hepatic and renal function as defined below:
• Leukocytes \> 3,000/micro-liter (mcl)
• Absolute neutrophil count \> 1,500/mcL
• Platelets \> 100,000/mcL
• Total bilirubin ≤1.5 upper limit of normal (ULN)
• Aspartate aminotransferase/ Alanine aminotransferase (AST/ALT) \< 2 ULN
• Creatinine ≤1.5 ULN OR
• Creatinine clearance \> 60 Ml/min/1.73 m2 for patients with creatinine levels above ULN calculated using Calvert formula
• Prior chemotherapy, hormonal and radiation therapy administered in the adjuvant setting will be allowed.

You may not qualify if:

• No prior treatment with ONC201
• Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
• The subjects who have not recovered to baseline or CTCAE ≤ Grade 1 from related toxicity to all prior therapies will be excluded. Patients with Non-serious adverse events such as alopecia, fatigue, weakness, loss of appetite and nausea that are non-significant will not be excluded.
• Any other prior malignancy from which the patient has been disease free for less than 3 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of any site.
• The subject is unable to swallow capsules
• Patients receiving any other investigational agents
• Patients with symptomatic brain metastases are excluded. Patients with asymptomatic and treated central nervous system (CNS) metastases may participate in this trial. The patient must have completed any prior treatment for CNS metastases \> 28 days prior to study entry including radiotherapy or surgery. Steroids for the treatment of brain metastasis are not permitted, and patients must be stable off steroid treatment for 4 weeks prior to enrollment
• Uncontrolled inter-current illness including, but not limited to ongoing or active infection. Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism.
• Active inflammatory gastrointestinal disease, chronic diarrhea (unless related to underlying malignancy or prior related treatment) or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within 6 months prior to study enrollment. Gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed.
• Known Human Immunodeficiency Virus (HIV)-positive patients on combination antiretroviral therapy
• Known history of Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection.
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or in the judgment of the investigator would make the patient inappropriate for entry into the study.
• Pregnant or breast feeding. Refer to section 4.4 for further details.

Sponsors & Collaborators

• Fox Chase Cancer Center: lead
• Oncoceutics, Inc.: collaborator

Study Sites (1)

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States

Location

MeSH Terms

Conditions

Endometrial Neoplasms

Interventions

TIC10 compound

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Study Officials

• Gina Mantia-Smaldone, MD

  Fox Chase Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 23, 2017
• First Posted: April 4, 2017
• Study Start: June 8, 2017
• Primary Completion: September 9, 2020
• Study Completion: September 9, 2020
• Last Updated: December 24, 2024

Record last verified: 2024-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)